These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 12423708)
1. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Gagné C; Bays HE; Weiss SR; Mata P; Quinto K; Melino M; Cho M; Musliner TA; Gumbiner B; Am J Cardiol; 2002 Nov; 90(10):1084-91. PubMed ID: 12423708 [TBL] [Abstract][Full Text] [Related]
2. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192 [TBL] [Abstract][Full Text] [Related]
3. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
5. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Dujovne CA; Ettinger MP; McNeer JF; Lipka LJ; LeBeaut AP; Suresh R; Yang B; Veltri EP; Am J Cardiol; 2002 Nov; 90(10):1092-7. PubMed ID: 12423709 [TBL] [Abstract][Full Text] [Related]
7. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
8. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
9. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP; Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255 [TBL] [Abstract][Full Text] [Related]
11. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. Chow D; Chen H; Glesby MJ; Busti A; Souza S; Andersen J; Kohrs S; Wu J; Koletar SL AIDS; 2009 Oct; 23(16):2133-41. PubMed ID: 19770624 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB; Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B; Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480 [TBL] [Abstract][Full Text] [Related]
14. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP; Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Pearson TA; Denke MA; McBride PE; Battisti WP; Gazzara RA; Brady WE; Palmisano J Mayo Clin Proc; 2006 Sep; 81(9):1177-85. PubMed ID: 16970214 [TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR; Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688 [TBL] [Abstract][Full Text] [Related]
17. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. Yu CC; Lai WT; Shih KC; Lin TH; Lu CH; Lai HJ; Hanson ME; Hwang JJ BMC Res Notes; 2012 May; 5():251. PubMed ID: 22621316 [TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Mikhailidis DP; Sibbring GC; Ballantyne CM; Davies GM; Catapano AL Curr Med Res Opin; 2007 Aug; 23(8):2009-26. PubMed ID: 17659159 [TBL] [Abstract][Full Text] [Related]
20. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Geiss HC; Otto C; Hund-Wissner E; Parhofer KG Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]